Nyxoah Initial Public Offering Multiple Times Over Subscribed and Early Closing Announced Read more about Nyxoah Initial Public Offering Multiple Times Over Subscribed and Early Closing Announced
Nyxoah Raises up to €85 million (US$100m) in Successful Initial Public Offering Read more about Nyxoah Raises up to €85 million (US$100m) in Successful Initial Public Offering
Nyxoah Announces Commencement of Trading of Shares on Euronext Brussels Read more about Nyxoah Announces Commencement of Trading of Shares on Euronext Brussels
Nyxoah announces the end of the Stabilisation Period and the Full Exercise of the Over-allotment Option in connection with its Initial Public Offering Read more about Nyxoah announces the end of the Stabilisation Period and the Full Exercise of the Over-allotment Option in connection with its Initial Public Offering
First Patient Implanted in the DREAM US Pivotal IDE Study, with the Genio® System for the Treatment of Obstructive Sleep Apnea (OSA) Read more about First Patient Implanted in the DREAM US Pivotal IDE Study, with the Genio® System for the Treatment of Obstructive Sleep Apnea (OSA)
Nyxoah to Participate in Annual Piper Sandler Healthcare Conference Read more about Nyxoah to Participate in Annual Piper Sandler Healthcare Conference
First US patient implanted in the DREAM pivotal IDE study, with the Genio® system for the treatment of Obstructive Sleep Apnea (OSA) Read more about First US patient implanted in the DREAM pivotal IDE study, with the Genio® system for the treatment of Obstructive Sleep Apnea (OSA)
Nyxoah announces full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA) Read more about Nyxoah announces full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)
Nyxoah and Vanderbilt University enter exclusive licensing agreement regarding next generation neurostimulation technologies to treat Obstructive Sleep Apnea (OSA) Read more about Nyxoah and Vanderbilt University enter exclusive licensing agreement regarding next generation neurostimulation technologies to treat Obstructive Sleep Apnea (OSA)
Nyxoah receives FDA approval for full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA) Read more about Nyxoah receives FDA approval for full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)